Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Novavax Inc.

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Sell rating on Novavax, with a price target of $8.00. Stran...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NVAX	$8.40	+5.26%	2.35M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NVAX	$8.40	+5.3%	2.35M
3
4
5
6

NVAX

NVAX

Get Novavax Inc. Data in Excel

Get Novavax Inc. Data in Excel